iSpecimen Stock to Reverse Split on Tuesday, April 28th (NASDAQ:ISPC)

iSpecimen Inc. (NASDAQ:ISPC)’s stock is scheduled to reverse split on Tuesday, April 28th. The 1-40 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, April 27th.

iSpecimen Stock Down 19.6%

Shares of NASDAQ:ISPC traded down $0.03 during midday trading on Friday, reaching $0.13. The company’s stock had a trading volume of 27,448,865 shares, compared to its average volume of 63,885,900. iSpecimen has a twelve month low of $0.10 and a twelve month high of $3.18. The stock has a fifty day moving average of $0.20 and a 200 day moving average of $0.40.

iSpecimen (NASDAQ:ISPC) last released its quarterly earnings data on Wednesday, April 1st. The company reported ($0.74) earnings per share for the quarter. The business had revenue of $0.05 million during the quarter. iSpecimen had a negative return on equity of 496.31% and a negative net margin of 543.37%.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a research note on Tuesday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Institutional Trading of iSpecimen

An institutional investor recently bought a new position in iSpecimen stock. Virtu Financial LLC purchased a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned 0.65% of iSpecimen as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 13.62% of the company’s stock.

iSpecimen Company Profile

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.